Laboratorio Reig Jofre Past Earnings Performance
Past criteria checks 2/6
Laboratorio Reig Jofre has been growing earnings at an average annual rate of 12.9%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 10.3% per year. Laboratorio Reig Jofre's return on equity is 4.5%, and it has net margins of 2.9%.
Key information
12.9%
Earnings growth rate
15.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 10.3% |
| Return on equity | 4.5% |
| Net Margin | 2.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Laboratorio Reig Jofre makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 334 | 10 | 98 | 0 |
| 30 Jun 24 | 334 | 9 | 96 | 0 |
| 31 Mar 24 | 326 | 9 | 92 | 0 |
| 31 Dec 23 | 318 | 9 | 90 | 0 |
| 30 Sep 23 | 316 | 12 | 87 | 0 |
| 30 Jun 23 | 298 | 10 | 86 | 0 |
| 31 Mar 23 | 286 | 10 | 84 | 0 |
| 31 Dec 22 | 274 | 8 | 82 | 0 |
| 30 Sep 22 | 262 | 4 | 77 | 0 |
| 30 Jun 22 | 256 | 5 | 77 | 0 |
| 31 Mar 22 | 245 | 3 | 76 | 0 |
| 31 Dec 21 | 240 | 5 | 74 | 0 |
| 30 Sep 21 | 237 | 6 | 77 | 0 |
| 30 Jun 21 | 234 | 5 | 76 | 0 |
| 31 Mar 21 | 234 | 6 | 76 | 0 |
| 31 Dec 20 | 234 | 6 | 76 | 0 |
| 30 Sep 20 | 229 | 8 | 75 | 0 |
| 30 Jun 20 | 229 | 6 | 72 | 0 |
| 31 Mar 20 | 219 | 6 | 70 | 0 |
| 31 Dec 19 | 206 | 5 | 68 | 0 |
| 30 Sep 19 | 199 | 7 | 68 | 0 |
| 30 Jun 19 | 188 | 9 | 67 | 0 |
| 31 Mar 19 | 188 | 9 | 66 | 0 |
| 31 Dec 18 | 185 | 9 | 65 | 0 |
| 30 Sep 18 | 185 | 10 | 60 | 0 |
| 30 Jun 18 | 179 | 9 | 59 | 0 |
| 31 Mar 18 | 175 | 9 | 58 | 0 |
| 31 Dec 17 | 172 | 9 | 58 | 0 |
| 30 Sep 17 | 164 | 5 | 58 | 0 |
| 30 Jun 17 | 164 | 7 | 57 | 0 |
| 31 Mar 17 | 164 | 8 | 57 | 0 |
| 31 Dec 16 | 161 | 8 | 55 | 0 |
| 30 Sep 16 | 160 | 5 | 55 | 0 |
| 30 Jun 16 | 159 | 5 | 54 | 0 |
| 31 Mar 16 | 156 | 5 | 53 | 1 |
| 31 Dec 15 | 157 | 9 | 53 | 0 |
| 31 Dec 14 | 133 | 9 | 41 | 0 |
| 30 Sep 14 | 122 | 9 | 33 | 0 |
Quality Earnings: 0RB1 has high quality earnings.
Growing Profit Margin: 0RB1's current net profit margins (2.9%) are lower than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RB1's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: 0RB1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0RB1 had negative earnings growth (-18.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.2%).
Return on Equity
High ROE: 0RB1's Return on Equity (4.5%) is considered low.